A study of a new drug, NPI-001 in healthy volunteers to test its safety and tolerability
Phase 1
Completed
- Conditions
- Retinitis pigmentosa (RP)
- Registration Number
- ACTRN12617000911392
- Lead Sponsor
- acuity Pharmaceuticals Pty Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method